他汀治疗与接受维持性透析的终末期肾病合并外周动脉疾病患者主要不良心血管及肢体结局的关联
这项回顾性队列研究利用台湾全民健康保险研究数据库,纳入2001年1月1日至2013年12月31日期间诊断为外周动脉疾病和血脂异常的长期维持性透析的肾衰竭患者,共10767例符合标准,其中3597例接受他汀治疗、7170例未接受;经1:1倾向评分匹配后纳入6470例(每组3235例)。随访3年时,他汀组心血管死亡(18.9% vs 21.2%;HR 0.86,95%CI 0.77-0.96;P=0.008)和全因死亡(33.3% vs 35.2%;HR 0.92,95%CI 0.84-0.996;P=0.04)风险显著低于非他汀组,EVT与截肢复合结局风险也显著降低(9.7% vs 11.2%;亚分布HR 0.85,95%CI 0.73-0.99;P=0.04)。剂量反应分析显示,他汀使用与全因死亡(趋势P=0.002)及EVT与截肢复合结局(趋势P=0.002)的风险降低呈剂量依赖性,但DDD分析中并非所有结果均具有统计学显著性。作者认为,他汀治疗可能对长期维持性透析的肾衰竭合并外周动脉疾病患者具有心血管和肢体保护获益。
要点
- 匹配队列随访3年,他汀组心血管死亡18.9% vs 非他汀组21.2%(HR 0.86,95%CI 0.77-0.96;P=0.008)。
- 匹配队列随访3年,他汀组全因死亡33.3% vs 非他汀组35.2%(HR 0.92,95%CI 0.84-0.996;P=0.04)。
- 匹配队列随访3年,他汀组EVT与截肢复合结局9.7% vs 非他汀组11.2%(亚分布HR 0.85,95%CI 0.73-0.99;P=0.04)。
- 调整后剂量反应分析中,全因死亡风险随他汀DDD增加而降低(DDD<0.50 HR 0.95、0.50-0.99 HR 0.92、1.00-1.49 HR 0.85、≥1.50 HR 0.79;趋势P=0.002)。
- EVT与截肢复合结局风险也随DDD增加而降低(DDD<0.50亚分布HR 0.79、0.50-0.99亚分布HR 0.78、1.00-1.49亚分布HR 0.82、≥1.50亚分布HR 0.58;趋势P=0.002),但DDD分析中并非所有结果均具有统计学显著性。
适用人群与场景
- 2001年1月1日至2013年12月31日期间诊断为外周动脉疾病和血脂异常、接受长期维持性透析的肾衰竭患者,共20731例中10767例符合预定研究标准(女性5593例[51.9%];平均[SD]年龄68.5[11.5]岁;均为台湾 ethnicity)。
- 倾向评分匹配队列6470例(平均[SD]年龄66.4[11.3]岁;女性3359例[51.9%]),他汀组与非他汀组各3235例。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用台湾全民健康保险研究数据库;数据于2021年6月8日至2022年6月2日分析。
- 共20731例长期维持性透析的肾衰竭合并外周动脉疾病和血脂异常患者被识别,10767例符合研究标准(他汀组3597例,非他汀组7170例);1:1倾向评分匹配后纳入6470例,每组3235例。
- 主要结局为全因死亡以及EVT与截肢的复合结局;其他结局包括心血管事件(心血管死亡、急性心肌梗死、缺血性卒中、心力衰竭住院)、主要不良肢体事件(新发跛行、新发危重肢体缺血、EVT、非创伤性截肢)和全因再入院;所有结局在随访1年和3年时评估。
- 随访3年,他汀组 vs 非他汀组:心血管死亡611例(18.9%) vs 685例(21.2%),HR 0.86(95%CI 0.77-0.96),P=0.008;全因死亡1078例(33.3%) vs 1138例(35.2%),HR 0.92(95%CI 0.84-0.996),P=0.04。
- 随访3年,他汀组 vs 非他汀组EVT与截肢复合结局:314例(9.7%) vs 361例(11.2%),亚分布HR 0.85(95%CI 0.73-0.99),P=0.04。
- 亚组分析结果在所有亚组变量中与主要分析一致。
- 调整后剂量反应分析中,与未接受他汀治疗相比,全因死亡风险随他汀DDD增加而降低:DDD<0.50 HR 0.95、DDD 0.50-0.99 HR 0.92、DDD 1.00-1.49 HR 0.85、DDD≥1.50 HR 0.79;趋势P=0.002。
- 调整后剂量反应分析中,与未接受他汀治疗相比,EVT与截肢复合结局风险随他汀DDD增加而降低:DDD<0.50亚分布HR 0.79、DDD 0.50-0.99亚分布HR 0.78、DDD 1.00-1.49亚分布HR 0.82、DDD≥1.50亚分布HR 0.58;趋势P=0.002;但DDD分析中并非所有结果均具有统计学显著性。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,他汀治疗可能对接受长期维持性透析的肾衰竭合并外周动脉疾病患者具有心血管和肢体保护获益。
- 本研究为观察性队列,他汀治疗与结局的关联不能等同于因果推荐;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Controversy exists regarding whether statin therapy has benefits for patients with kidney failure, and the consequences of statin therapy for patients with kidney failure and concomitant peripheral artery disease (PAD) are particularly uncertain.
OBJECTIVE: To evaluate the association of statin therapy with cardiovascular (CV) and limb outcomes among patients with kidney failure and concomitant PAD and dyslipidemia who are receiving long-term maintenance dialysis.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Taiwan National Health Insurance Research Database. A total of 20 731 patients with kidney failure receiving long-term maintenance dialysis who were diagnosed with PAD and dyslipidemia between January 1, 2001, and December 31, 2013, were identified, and 10 767 patients met study criteria. Data were analyzed from June 8, 2021, to June 2, 2022.
MAIN OUTCOMES AND MEASURES: Primary outcomes were all-cause death and the composite of endovascular therapy (EVT) and amputation. Other outcomes of interest included CV events (CV death, acute myocardial infarction, ischemic stroke, and hospitalization for heart failure), major adverse limb events (new-onset claudication, new-onset critical limb ischemia, EVT, and nontraumatic amputation), and all-cause readmission. All outcomes were examined at 1 year and 3 years of follow-up. To minimize selection bias, propensity score matching on a 1:1 ratio was performed among patients receiving statin therapy (statin group) and patients not receiving statin therapy (nonstatin group). A defined daily dose (DDD) approach was used to evaluate whether the association of statin therapy with the risk of primary outcomes was dose dependent.
RESULTS: Among 20 731 patients with kidney failure and concomitant PAD and dyslipidemia receiving long-term maintenance dialysis, 10 767 patients (5593 women [51.9%]; mean [SD] age, 68.5 [11.5] years; all of Taiwanese ethnicity) met the predetermined study criteria; of those, 3597 patients were receiving statin therapy, and 7170 were not. A total of 6470 patients (mean [SD] age, 66.4 [11.3] years; 3359 women [51.9%]) were included in the 1:1 propensity score-matched cohort, with 3235 patients in each group (statin and nonstatin). The incidence and risk of CV and all-cause death were significantly lower in the statin group vs the nonstatin group at 3 years of follow-up (CV death: 611 patients [18.9%] vs 685 patients [21.2%]; hazard ratio [HR], 0.86 [95% CI, 0.77-0.96]; P = .008; all-cause death: 1078 patients [33.3%] vs 1138 patients [35.2%]; HR, 0.92 [95% CI, 0.84-0.996]; P = .04). Statin use was also associated with a significantly lower incidence and risk of the composite adverse limb outcome of EVT and amputation at 3 years of follow-up (314 patients [9.7%] vs 361 patients [11.2%]; subdistribution HR, 0.85 [95% CI, 0.73-0.99]; P = .04). Results of subgroup analyses were consistent with those of the primary analysis across all subgroup variables. In the adjusted dose-response analysis, the risk reduction associated with statin use increased in a dose-dependent manner for both all-cause death (HR: 0.95 for DDD <0.50, 0.92 for DDD 0.50-0.99, 0.85 for DDD 1.00-1.49, and 0.79 for DDD ≥1.50; P = .002 for trend) and the composite outcome of EVT and amputation (subdistribution HR: 0.79 for DDD <0.50, 0.78 for DDD 0.50-0.99, 0.82 for DDD 1.00-1.49, and 0.58 for DDD ≥1.50; P = .002 for trend) compared with no statin therapy; however, not all findings in the DDD analysis were statistically significant.
CONCLUSIONS AND RELEVANCE: In this cohort study, statin therapy was associated with reductions in the risk of all-cause death, CV death, and the composite adverse limb outcome of EVT and amputation. These findings suggest that statin therapy may have protective CV and limb benefits for patients with kidney failure and concomitant PAD who are receiving long-term maintenance dialysis.
参考来源
- Lo HY, Lin YS, Lin DS, et al. Association of Statin Therapy With Major Adverse Cardiovascular and Limb Outcomes in Patients With End-stage Kidney Disease and Peripheral Artery Disease Receiving Maintenance Dialysis. JAMA Netw Open. 2022. PMID: 36048442. doi:10.1001/jamanetworkopen.2022.29706
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。